ScholarLens Back to search
2015•Pharmaceutical MedicineOpen access

Do Molecular Structures of Migraine Drugs Point to a Common Cause of this Elusive Disease and Suggest Future Drug Designs?

Mark J. Brinsden, Ian C. Shaw

Open full text 2 citations

Abstract

We should, perhaps, consider migraine as a two-stage disorder. Stage 1 is the underlying biochemical disorder (migraine disorder) that predisposes the sufferer to stage 2, which is the manifestation of the disorder as a migraine headache.

Open-access reader

About this research paper

What this paper is about

We should, perhaps, consider migraine as a two-stage disorder. Stage 1 is the underlying biochemical disorder (migraine disorder) that predisposes the sufferer to stage 2, which is the manifestation of the disorder as a migraine headache.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

We should, perhaps, consider migraine as a two-stage disorder. Stage 1 is the underlying biochemical disorder (migraine disorder) that predisposes the sufferer to stage 2, which is the manifestation of the disorder as a migraine headache.

Key concepts: Migraine, Triptans, Medicine, Headaches, Disease, Drug, Primary headache, Neurological disorder

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Do Molecular Structures of Migraine Drugs Point to a Common Cause of this Elusive Disease and Suggest Future Drug Designs? — Research Paper | ScholarLens